Cover Image
市場調查報告書

CellCentric Ltd.的產品平台分析

CellCentric Ltd. - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 276030
出版日期 內容資訊 英文 22 Pages
訂單完成後即時交付
價格
Back to Top
CellCentric Ltd.的產品平台分析 CellCentric Ltd. - Product Pipeline Review - 2014
出版日期: 2014年07月31日 內容資訊: 英文 22 Pages
簡介

CellCentric Ltd.ha是藉由去泛素化酶的研究,著重於前列腺癌治療藥的開發計劃之藥物研發企業。

本報告提供CellCentric Ltd.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

CellCentric Ltd.概要

  • 概要
  • 企業資料
  • 主要資訊

CellCentric Ltd.:R&D概要

  • 主要的治療範圍

CellCentric Ltd.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品

CellCentric Ltd.:開發中產品概況

  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

CellCentric Ltd.:藥物簡介

  • Small Molecules to Inhibit Deubiquitinase for Castrate Resistant Prostate Cancer
  • Small Molecules to Inhibit Histone Demethylase for Cancer
  • Small Molecules to inhibit HMT for Cancer

CellCentric Ltd.:開發平台分析

  • 標的別
  • 各分子類型
  • 各作用機制

CellCentric Ltd.:最新的開發中產品資訊

CellCentric Ltd.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06170CDB

Summary

Global Markets Direct's, 'CellCentric Ltd. - Product Pipeline Review - 2014', provides an overview of the CellCentric Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of CellCentric Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of CellCentric Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of CellCentric Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the CellCentric Ltd.'s pipeline products

Reasons to buy

  • Evaluate CellCentric Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of CellCentric Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the CellCentric Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of CellCentric Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of CellCentric Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of CellCentric Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • CellCentric Ltd. Snapshot
    • CellCentric Ltd. Overview
    • Key Information
    • Key Facts
  • CellCentric Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • CellCentric Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • CellCentric Ltd. - Pipeline Products Glance
    • CellCentric Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • CellCentric Ltd. - Drug Profiles
    • Small Molecules to Inhibit Deubiquitinase for Castrate Resistant Prostate Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Histone Demethylase for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to inhibit HMT for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • CellCentric Ltd. - Pipeline Analysis
    • CellCentric Ltd. - Pipeline Products by Target
    • CellCentric Ltd. - Pipeline Products by Molecule Type
    • CellCentric Ltd. - Pipeline Products by Mechanism of Action
  • CellCentric Ltd. - Recent Pipeline Updates
  • CellCentric Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • CellCentric Ltd., Key Information
  • CellCentric Ltd., Key Facts
  • CellCentric Ltd. - Pipeline by Indication, 2014
  • CellCentric Ltd. - Pipeline by Stage of Development, 2014
  • CellCentric Ltd. - Monotherapy Products in Pipeline, 2014
  • CellCentric Ltd. - Out-Licensed Products in Pipeline, 2014
  • CellCentric Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2014
  • CellCentric Ltd. - Preclinical, 2014
  • CellCentric Ltd. - Discovery, 2014
  • CellCentric Ltd. - Pipeline by Target, 2014
  • CellCentric Ltd. - Pipeline by Molecule Type, 2014
  • CellCentric Ltd. - Pipeline Products by Mechanism of Action, 2014
  • CellCentric Ltd. - Recent Pipeline Updates, 2014
  • CellCentric Ltd., Other Locations

List of Figures

  • CellCentric Ltd. - Pipeline by Top 10 Indication, 2014
  • CellCentric Ltd. - Pipeline by Stage of Development, 2014
  • CellCentric Ltd. - Monotherapy Products in Pipeline, 2014
  • CellCentric Ltd. - Pipeline by Top 10 Target, 2014
  • CellCentric Ltd. - Pipeline by Top 10 Molecule Type, 2014
  • CellCentric Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top